4.007,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
  • Broschiertes Buch

This encyclopedia details pharmaceutical science best practices for equipment used, processes for manufacturing, options for packaging, and routes for drug delivery, and a thorough understanding of the choices behind each method. The regulations, safety aspects, patent guidance, and methods of analysis are also given, making this a must-have reference guide for all laboratories and libraries in the field. The Fourth Edition offers 29 new chapters ranging from biomarkers, computational chemistry, and contamination control to high-throughput screening, orally disintegrating tablets, and quality by design.…mehr

Produktbeschreibung
This encyclopedia details pharmaceutical science best practices for equipment used, processes for manufacturing, options for packaging, and routes for drug delivery, and a thorough understanding of the choices behind each method. The regulations, safety aspects, patent guidance, and methods of analysis are also given, making this a must-have reference guide for all laboratories and libraries in the field. The Fourth Edition offers 29 new chapters ranging from biomarkers, computational chemistry, and contamination control to high-throughput screening, orally disintegrating tablets, and quality by design.
Autorenporträt
James Swarbrick, D.Sc., Ph.D., is the president of PharmaceuTech, Inc., Pinehurst, North Carolina, USA. He has served in a number of industrial and academic positions, including director of product development at Sterling-Winthrop Research Institute, Rensselaer, New York, and vice president for research and development and vice president for scientific affairs at AAIPharma, Wilmington, North Carolina, USA. Prior to joining AAIPharma, he was a professor and chairman of the Division of Pharmaceutics at the University of North Carolina at Chapel Hill School of Pharmacy. Dr. Swarbrick is a Fellow of the American Association of Pharmaceutical Sciences, the Royal Society of Chemistry, and the Royal Pharmaceutical Society of Great Britain. He has also served as a member and chairman of the FDA's Generic Drugs Advisory Committee, as chairman of the PhRMA Foundation's Pharmaceutics Advisory Committee, as well as a member of the PhRMA Foundation's Scientific Advisory Committee.